+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tuberculosis Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 283 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227810

Global Tuberculosis Therapeutics Market to Reach $1.1 Billion by 2030

The global market for Tuberculosis Therapeutics estimated at US$863 Million in the year 2022, is projected to reach a revised size of US$1.1 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2022-2030. Active TB, one of the segments analyzed in the report, is projected to record 2.9% CAGR and reach US$654.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Latent TB segment is readjusted to a revised 2.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $235.1 Million, While China is Forecast to Grow at 4.7% CAGR

The Tuberculosis Therapeutics market in the U.S. is estimated at US$235.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$208.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Select Competitors (Total 37 Featured) -

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Tuberculosis Therapeutics

What is the estimated value of the Global Market for Tuberculosis Therapeutics?

The Global Market for Tuberculosis Therapeutics was estimated to be valued at $863 Million in 2022.

What is the growth rate of the Global Market for Tuberculosis Therapeutics?

The growth rate of the Global Market for Tuberculosis Therapeutics is 3.1%, with an estimated value of $1100 Million by 2030.

What is the forecasted size of the Global Market for Tuberculosis Therapeutics?

The Global Market for Tuberculosis Therapeutics is estimated to be worth $1100 Million by 2030.

Who are the key companies in the Global Market for Tuberculosis Therapeutics?

Key companies in the Global Market for Tuberculosis Therapeutics include AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Lupin Ltd., Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Panacea Biotec Ltd. and Pfizer, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tuberculosis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 3: World 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 6: World 18-Year Perspective for Active TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 9: World 18-Year Perspective for Latent TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 12: World 18-Year Perspective for First-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 15: World 18-Year Perspective for Second-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
  • Table 16: World Tuberculosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 19: USA 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 22: USA 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 25: Canada 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 28: Canada 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
JAPAN
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 31: Japan 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 34: Japan 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
CHINA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: China Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 37: China 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: China Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 40: China 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
EUROPE
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 43: Europe 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 46: Europe 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 49: Europe 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
FRANCE
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: France Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 52: France 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: France Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 55: France 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
GERMANY
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 58: Germany 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 61: Germany 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 64: Italy 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 67: Italy 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
UNITED KINGDOM
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 69: UK Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 70: UK 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 72: UK Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 73: UK 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
SPAIN
  • Table 74: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 75: Spain Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 76: Spain 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 77: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 78: Spain Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 79: Spain 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
RUSSIA
  • Table 80: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 81: Russia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 82: Russia 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 83: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 84: Russia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 85: Russia 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 88: Rest of Europe 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 91: Rest of Europe 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
ASIA-PACIFIC
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 94: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 97: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
  • Table 100: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
AUSTRALIA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Panacea Biotec Ltd.
  • Pfizer, Inc.